Vical Raises $20M in Private Stock Placements

Vical, the San Diego biotech developing a vaccine for the H1N1 swine flu, says it has raised about $20 million in private stock sales arranged with several institutional investors, via private placement memorandum. The overall deal includes a $4.6 million commitment announced today from Special Situations Funds, a New York institutional investor.

The company says it is raising approximately $15.4 million from two other institutional investors, including the Pittsburgh, PA-based Federated Kaufmann Fund, through a related stock-and-options deal. Vical says Federated Kaufmann and Special Situations Funds are among the biotech’s largest stockholders, but the company did not identify its third investor.

Vical says it expects to receive net proceeds of approximately $18.9 million from the total offering after deducting fees and expenses from the deal. The company plans to use proceeds for ongoing programs and other general corporate purposes.

Vical said recently it has completed development of a prototype H1 vaccine, and taken the preliminary steps necessary to begin human clinical trials. Assuming that animal testing is successful, the company says it is ready to advance to large-scale manufacturing of the vaccine for human clinical trials to be conducted by the U.S. Navy. In a statement, Vical CEO Vijay Samant said, “The ongoing H1N1 influenza outbreaks remain a focal point of international discussions regarding the need for and feasibility of producing an H1 vaccine. We have already demonstrated the speed of our technology by producing an H1 vaccine and initiating animal testing while others are still assessing the situation.”

Vical Raises $20M in Private Stock Placements

About PPM

PPM is the leading U.S. entrepreneurial firm that specializes in writing private placement memorandums (PPM) and linking investors with entrepreneurs.

Since 1999, the founders of PPM have provided professional business writing services, such as a PPM or business plan, to more than 2,000 businesses worldwide. Our company is considered to be the most cost effective, efficient consultants for private placement memorandum development in the United States. We are Wall Street’s, and by extension, the New York private placement (PPM) leaders.’s main service is the creation of private placement memorandum regulation d (Reg. d) documents. However, we offer much more. In case the entrepreneur needs additional services, such as a business plan, website, or additional legal work, PPM can create one pricing package for all required documentation or service. Because we simultaneously work with many companies both in and out of the U.S., the ability to adapt to the individual needs – as well as to regional and global demands – helps our clients save needed capital and time.

We are leaders in:

• San Diego Private Placement
• Biotech Private Placement
• Technology Private Placement
• Debt Private Placement
• Equity Private Placement
• Technology Private Placement Memorandum Writing
• San Diego, California Private Placement Memorandum Writing
• Biotechnology Private Placement Memorandum Writing
• Debt Private Placement Memorandum Writing
• Equity Private Placement Memorandum Writing